platinum tungsten wire that is thinner than hair is performed to weave and welding processes. In the laboratory of Shanghai Wobi Medical Technology Co., Ltd. (hereinafter referred to as "Wobi Medical") located in Pudong , R&D personnel are developing the first neurointerventional embolization product in China that has been certified by the US FDA, EU CE and Japan PMDA - Avenir mechanical release spring coil.
Intracranial coil is a common device in the treatment of cerebrovascular rupture aneurysms. Neurovascular interventional treatment requires extremely high accuracy and the lowest error range, and is the most challenging vascular area in clinical medicine. In the field of neurointervention, Woby Medical has become the only company in China that has successfully entered the international market, formed sales scale in major developed markets such as the United States and Europe, competed with international giants and gained international recognition, and has been rated as the "specialized, specialized and innovative" enterprise in Shanghai in 2021.
This year, Wobi Medical has a "new identity" - the fifth China International Import Expo exhibitors. The company will fully demonstrate its global innovations in the field of neurointervention and the overall solution for stroke at its debut at the CIIE. At the same time, Wobi Medical will announce a series of cooperation projects during the CIIE, in order to further promote the clinical development of China's stroke treatment field and work with relevant parties to serve more patients.
Global Neurological Intervention Field
Frontier Innovation Products are launched in
The reporter learned that as a global innovative medical technology company, Wobi Medical will exhibit related products for the treatment of hemorrhagic and ischemic stroke in this CIIE, including pEGASUS intracranial stent (including hydrophilic coating), p48/p64 blood flow-guided dense mesh stent (including hydrophilic coating), and pRESET thrombectomy stent.
Among them, pEGASUS intracranial stent (including hydrophilic coating) is a self-expanding tubular vascular implant that can conduct interventional treatment of cervical spine and intracranial lesion artery. It is especially suitable for stent-assisted treatment of wide-neck aneurysms with hemorrhagic stroke. It has obtained the EU CE certification and marketing authorization, and clinical trials in China have also been launched. p64 in the p48/p64 blood flow-guided dense mesh stent (including hydrophilic coating) series is the world's first fully released and recyclable blood flow-guided dense mesh stent. It is a powerful tool for treatment of complex intracranial aneurysms and has obtained EU CE certification and marketing authorization.
It is worth mentioning that the patented HPC coating used in these products, that is, the hydrophilic coating, can put invisible protective clothing on blood vessels, effectively reducing the risk of thrombosis caused by implants.
Wobi Medical CEO and Founder Michael Alper (Amuk) said: "The CIIE is a powerful platform to accelerate the implementation of top medical devices in China's top technologies and products. Wobi Medical actively participated in the exhibition with breakthrough innovations in this field, demonstrating our enthusiasm and confidence in the Chinese market. We hope to use the international advanced technology and R&D concept system to provide strong and comprehensive support to Chinese doctors and patients, help the vast number of cerebral vascular patients in China to regain their health, and then implement Wobi Medical's corporate vision - to become the world's medical technology company that saves the most lives of stroke patients."
It is reported that during the CIIE, Wobi Medical will also announce the launch of the pilot implementation of pEGASUS intracranial stent (including hydrophilic coating) in Boao, Hainan, and leverage the "first-test" policy to accelerate the introduction of advanced products to China and benefit Chinese patients. At the same time, Wobi Medical will also carry out a number of innovation-based cooperation with the Alliance for Innovation and Transformation of Neuromedical Sciences (CNIT), to jointly explore a win-win situation with innovation as the cornerstone, and work together to promote the development of China's neurointervention industry.
All products are produced in Pudong
proves to the world "Made in China" strength
In April this year, Wobi Medical completed the acquisition of German global neurointervention company Phenox for 3.5 billion yuan. This is one of the largest cross-border mergers and acquisitions in the global medical device industry in recent years, and the company has made important substantial progress towards internationalization.
"We have completed the acquisition of phenox GmbH, a leading global innovation and technology company in Germany's global neurointervention industry, making the company's product portfolio and market coverage more globally competitive." Anmuke said, "We are also working hard to introduce phenox GmbH technology products into China to benefit Chinese patients; at the same time, we also hope to bring our own products to the global market."
As a global medical technology company, Wobby Medical has always given priority to the Chinese market. At present, Wobi Medical has set up a production base and R&D center in Pudong. In 2018, the first independently developed product, Avenir mechanical release spring coil, obtained the US FDA certification, obtained the EU CE certification in 2019, and officially entered the international market in the second half of 2019, becoming the only domestic spring coil product sold in Europe and the United States at that time. As a Chinese independent brand spring coil that competes directly with leading international brands in the European and American markets, Avenir has achieved commercial operations in more than 30 countries or regions with its outstanding performance. In addition, many innovative products have also obtained marketing licenses in countries and regions such as China and the United States.
broke the monopoly of high-end medical devices for neural intervention, and Woby Medical has proved to the world the strength of creation and production in China. At present, all Woby Medical's products are produced in Pudong, and the newly acquired phenox GmbH product line is also planned to be produced in China in the future.
"China has a policy soil and ecosystem that encourages medical innovation. In this way, we participated in the CIIE and the Pudong government gave great support." Liu Bing, chairman and founder of Wobby Medical, said, "There are a large number of clinical needs for stroke that need to be solved urgently, and many outstanding partners adhere to the same values and vision as Wobby. Wobby Medical has been actively exploring diversified cooperation with stakeholders such as governments, industry associations, societies, clinical and academic institutions, and looks forward to working with all parties to strive to bring global innovative solutions and advanced treatment concepts to China as soon as possible, and promote the high-quality and efficient development of China's stroke prevention and control system."
Editor-in-charge Liu Wanxin
Text Yang Zhenying
Source Pudong releases
